A. Decreased risk of AIDS–associated events (ie, death from AIDS, any AIDS-defining event, or Hodgkin lymphoma), but increased risk of non–AIDS-related events (eg, cardiovascular disease, end-stage renal disease, non–AIDS-defining cancer) B. Decreased risk of non–AIDS-related events, but similar risk of AIDS-associated events C. Lower mortality risk regardless of the patient's CD4 T lymphocyte (CD4) count D. No significant change in the risk of HIV transmission

A. More protease inhibitor–based regimens are identified as first-line ART options in the 2016 guidelines B. Unlike the 2010 guidelines, the 2016 guidelines do not include any protease inhibitor–based regimens as first-line ART options C. More integrase-inhibitor–based regimens are identified as first-line ART options in the 2016 guidelines D. Only 1 nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen is included as a first-line ART option in both the 2010 and 2016 guidelines

A. Meningococcal conjugate B. Hepatitis B series C. Varicella D. Human papillomavirus (HPV) series

A. Pharmacist plus primary care provider (PCP) B. HIV specialist plus mental health professional C. Nurse plus mental health professional plus PCP D. Pharmacist plus care coordinator plus PCP

A. Consult treatment guidelines and primary literature B. Obtain a complete ART history C. Evaluate previous resistance testing results D. Ensure current virologic suppression E. Consider comorbid conditions and concomitant medications